Larimar Therapeutics appoints John B. Harlow, Jr. as president and COO
Larimar Therapeutics, Inc., a biotech company with a market capitalization of $326 million, has appointed John B. Harlow, Jr. as its new president and chief operating officer, effective immediately. Mr. Harlow, aged 51, previously served as chief commercial officer at Esperion Therapeutics, Inc. Mr. Harlow's appointment comes as Larimar faces near-term challenges, with its shares dropping 17% over the past week to trade at $3.14.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
